Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: OTC drug interaction labeling

This article was originally published in The Tan Sheet

Executive Summary

OTC drug interaction labeling: FDA Oct. 4 Federal Register notice would permit labeling to shorten the format for interaction warnings. The current required drug interaction precaution begins with the statement "Drug interaction precaution" followed by "Do not use this product." Under the proposed format, the words "`Drug interaction precaution' would no longer be needed and the precaution would begin with `Do not use with' and could be followed by `a prescription drug for....'" FDA says that "this approach would shorten the required labeling without changing the meaning," the agency notes. Written comments on the proposed rule are due by Jan. 2. The proposed modification would serve as an additional alternative to interchangeable terms previously suggested by the agency in August 1994 ("The Tan Sheet" Aug. 8, 1994, p. 7)...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts